Lilly pauses UK Mounjaro orders to stop pre-price-rise stockpiling

Eli Lilly temporarily paused UK shipments of Mounjaro, its tirzepatide drug for diabetes and obesity, after pharmacies began buying ahead of a steep price increase set for September ^[1][2]. The company said it would resume taking orders on September 1 ^[1].

Lilly framed the move as a way to manage supply and keep the drug accessible to patients. The company said it has allocations in place for pharmacies and providers that order from it, and it cited UK legal protections meant to stop "inappropriate" stockpiling by providers ^[1][2]. A Lilly spokesperson described the pause as a "month-end cut off for orders" ^[2]. The company also said, "We encourage patients to only order based on their current treatment plan, to reduce the risk of localized disruption" ^[2].

The pause came two weeks after Lilly said it would raise Mounjaro's UK list price by as much as 170% starting September 1 ^[1][2]. The price hike applies to private providers who negotiate their own discounts, not the UK's National Health Service ^[2]. For a month's supply of the highest dose, the price would rise from 122 pounds to 330 pounds, or about $164.81 to $445.80 at the time ^[1]. Pharmacies reportedly saw panic buying after Lilly announced the increase, and the company allegedly told two British wholesalers to temporarily stop taking Mounjaro orders in response to the demand spike ^[2].

Lilly has tied the UK price increase to a broader push by the Trump administration for drugmakers to raise medicine prices in Europe so that US prices can come down, an approach known as Most Favored Nation pricing ^[1][2]. Lilly said in a statement that "prices for medicines paid by governments and health systems need to increase in other developed markets like Europe in order to make them lower in the US," adding that it has "intensified efforts to align prices across developed countries" ^[2]. It is not yet known how price adjustments will play out in countries beyond the UK ^[2].

Why it matters for patients

This episode happened in the UK, not the US, so it does not directly change what American patients pay for Mounjaro or Zepbound. But it shows how a price change announced in one country can quickly ripple into supply problems there, as pharmacies and providers try to buy at the old, lower price before it changes ^[1][2]. For US patients watching drug pricing debates, it is a real-world example of how international price shifts and government pressure on drugmakers can affect whether a medicine is actually available on pharmacy shelves, not just what it costs on paper.

Lilly's CEO, David Ricks, has also warned that importing "foreign price controls" into the US system could bring "the worst of two worlds": the low output of Europe's biopharma sector combined with the high out-of-pocket costs and distorted prices of the US insurance market ^[2]. That comment suggests Lilly itself sees tension between aligning prices globally and keeping supply stable, which is relevant to anyone trying to predict how US prices or availability might shift as these international pricing talks continue.

What happens next

Lilly said it planned to resume normal Mounjaro order processing in the UK on September 1, when the new, higher UK list price was also set to take effect ^[1][2]. Beyond the UK, it is not yet known how or when Lilly will adjust prices in other countries, including the United States ^[2]. Lilly has separately taken steps in the US, such as cutting insulin prices by 70% in 2023 and running a direct-to-consumer platform called LillyDirect that offers some medicines to cash-paying patients at a discount from list price ^[2].